Margrave David R. 4
4 · Lantern Pharma Inc. · Filed Nov 2, 2021
Insider Transaction Report
Form 4
Margrave David R.
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-10-29+26,100→ 26,100 totalExercise: $10.21Exp: 2031-10-29→ Common Stock (26,100 underlying)
Footnotes (1)
- [F1]The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 36-month period commencing upon November 29, 2021.